Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer

被引：7

作者：

Hata A. ^{[1
]}

Katakami N. ^{[1
]}

Fujita S. ^{[1
]}

Takatori K. ^{[2
]}

Horai A. ^{[2
]}

Kitajima N. ^{[2
]}

Terashima K. ^{[3
]}

机构：

[1] Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Chuo-ku, Kobe 650-0047, 2-2, Minatojima-minamimachi

[2] Department of Internal Medicine, Kasai City Hospital, Kasai

[3] Department of Radiology, Kasai City Hospital, Kasai

来源：

Journal of Gastrointestinal Cancer | 2013年 / 44卷 / 4期

关键词：

Bevacizumab; Irinotecan; Cetuximab; Gefitinib; Panitumumab;

D O I：

10.1007/s12029-012-9453-7

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：456 / 459

页数：3

共 15 条

[1]

Jemal A., Siegel R., Ward E., Et al., Cancer statistics, 2009, CA Cancer J Clin, 59, pp. 225-249, (2009)

[2]

Hurwitz H., Fehrenbacher L., Novotny W., Et al., Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, pp. 2335-2342, (2004)

[3]

Saltz L.B., Clarke S., Diaz Rubio E., Et al., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study, J Clin Oncol, 26, pp. 2013-2019, (2008)

[4]

Bokemeyer C., Bondarenko I., Makhson A., Et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, 27, pp. 663-671, (2009)

[5]

Douillard J.Y., Siena S., Cassidy J., Et al., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study, J Clin Oncol, 28, pp. 4697-4705, (2010)

[6]

Santini D., Vincenzi B., Addeo R., Et al., Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance?, Ann Oncol, 23, pp. 2313-2318, (2012)

[7]

Saif M.W., Kaley K., Chu E., Et al., Safety and efficacy of panitumumab therapy after progression with cetuximab: Experience at two institutions, Clin Colorectal Cancer, 9, pp. 315-318, (2010)

[8]

Power D.G., Shah M.A., Asmis T.R., Et al., Safety and efficacy of panitumumab following cetuximab: Retrospective review of the Memorial Sloan-Kettering experience, Investig New Drugs, 28, pp. 353-360, (2010)

[9]

Heun J., Holen K., Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report, Clin Colorectal Cancer, 6, pp. 529-531, (2007)

[10]

Langerak A., River G., Mitchell E., Et al., Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: A series of four case reports, Clin Colorectal Cancer, 8, pp. 49-54, (2009)

← 1 2 →